PF-6678552(PF-6678552) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用机制-

治疗领域-

在研适应症-

非在研适应症-

原研机构

Pfizer Inc.

在研机构-

非在研机构

Pfizer Inc.

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

2

项与 PF-6678552 相关的临床试验

NCT02079922 / Completed临床1期

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of PF-06678552 After Administration Of Multiple Escalating Oral Doses In Healthy Adult Subjects

PF-06678552 is a new compound proposed for the treatment of hypercholesteremia. The primary purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of PF-06678552 in healthy subjects.

开始日期2014-03-01

申办/合作机构

Pfizer Inc.

NCT01992614 / Completed临床1期

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of PF-06678552 After Fed And Fasted Administration Of Single Escalating Oral Doses In Healthy Subjects

PF-06678552 is a new compound proposed for the treatment of hypercholesteremia. The primary purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of PF-06678552 in healthy subjects.

开始日期2013-12-01

申办/合作机构

Pfizer Inc.

100 项与 PF-6678552 相关的临床结果

登录后查看更多信息

100 项与 PF-6678552 相关的转化医学

登录后查看更多信息

100 项与 PF-6678552 相关的专利（医药）

登录后查看更多信息

100 项与 PF-6678552 相关的药物交易

登录后查看更多信息